Q2 EPS Estimates for Gilead Sciences Increased by Analyst

Gilead Sciences, Inc. (NASDAQ:GILD) – Equities research analysts at Zacks Research lifted their Q2 2025 earnings per share (EPS) estimates for shares of Gilead Sciences in a report issued on Thursday, January 16th. Zacks Research analyst E. Bagri now forecasts that the biopharmaceutical company will post earnings per share of $1.75 for the quarter, up from their prior forecast of $1.72. The consensus estimate for Gilead Sciences’ current full-year earnings is $4.36 per share. Zacks Research also issued estimates for Gilead Sciences’ Q4 2025 earnings at $1.86 EPS, FY2025 earnings at $7.12 EPS, Q3 2026 earnings at $2.19 EPS, Q4 2026 earnings at $2.03 EPS and FY2026 earnings at $7.55 EPS.

A number of other research analysts have also recently commented on GILD. Wells Fargo & Company increased their price objective on Gilead Sciences from $100.00 to $105.00 and gave the stock an “overweight” rating in a research note on Thursday, November 7th. Needham & Company LLC reaffirmed a “hold” rating on shares of Gilead Sciences in a research report on Thursday, November 7th. Citigroup started coverage on Gilead Sciences in a research report on Thursday, November 14th. They set a “buy” rating and a $125.00 target price on the stock. Morgan Stanley raised Gilead Sciences from an “equal weight” rating to an “overweight” rating and increased their target price for the company from $87.00 to $113.00 in a research report on Friday, January 10th. Finally, Leerink Partners upgraded Gilead Sciences from a “market perform” rating to an “outperform” rating and increased their price objective for the company from $74.00 to $96.00 in a report on Monday, October 21st. Eleven analysts have rated the stock with a hold rating, thirteen have given a buy rating and four have assigned a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $97.96.

Gilead Sciences Stock Performance

NASDAQ GILD opened at $92.96 on Monday. The company has a quick ratio of 1.10, a current ratio of 1.26 and a debt-to-equity ratio of 1.24. The firm has a market cap of $115.85 billion, a price-to-earnings ratio of 1,032.89, a price-to-earnings-growth ratio of 1.29 and a beta of 0.18. Gilead Sciences has a twelve month low of $62.07 and a twelve month high of $98.90. The business has a 50-day moving average price of $91.65 and a 200-day moving average price of $84.38.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.58 by $0.44. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The business had revenue of $7.55 billion during the quarter, compared to analyst estimates of $7.01 billion. During the same quarter in the previous year, the company posted $2.29 earnings per share. Gilead Sciences’s revenue for the quarter was up 7.0% on a year-over-year basis.

Gilead Sciences Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, December 30th. Stockholders of record on Friday, December 13th were given a dividend of $0.77 per share. This represents a $3.08 annualized dividend and a dividend yield of 3.31%. The ex-dividend date of this dividend was Friday, December 13th. Gilead Sciences’s dividend payout ratio is 3,422.22%.

Insider Buying and Selling

In related news, CFO Andrew D. Dickinson sold 248,645 shares of the firm’s stock in a transaction dated Friday, November 29th. The shares were sold at an average price of $92.76, for a total transaction of $23,064,310.20. Following the transaction, the chief financial officer now directly owns 138,919 shares of the company’s stock, valued at approximately $12,886,126.44. This trade represents a 64.16 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Merdad Parsey sold 25,590 shares of the firm’s stock in a transaction dated Wednesday, November 6th. The stock was sold at an average price of $91.50, for a total transaction of $2,341,485.00. Following the transaction, the insider now directly owns 99,599 shares in the company, valued at approximately $9,113,308.50. This represents a 20.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 456,234 shares of company stock valued at $42,130,461 in the last 90 days. 0.29% of the stock is owned by insiders.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Bellevue Group AG boosted its holdings in Gilead Sciences by 18.2% during the 3rd quarter. Bellevue Group AG now owns 46,027 shares of the biopharmaceutical company’s stock worth $3,859,000 after acquiring an additional 7,093 shares during the last quarter. Quantinno Capital Management LP boosted its holdings in shares of Gilead Sciences by 149.5% in the 3rd quarter. Quantinno Capital Management LP now owns 81,620 shares of the biopharmaceutical company’s stock worth $6,843,000 after buying an additional 48,910 shares during the last quarter. Legal & General Group Plc boosted its holdings in shares of Gilead Sciences by 0.8% in the 2nd quarter. Legal & General Group Plc now owns 12,414,268 shares of the biopharmaceutical company’s stock worth $851,743,000 after buying an additional 93,068 shares during the last quarter. IRON Financial LLC purchased a new position in shares of Gilead Sciences in the 3rd quarter worth about $830,000. Finally, Capital Investment Advisors LLC boosted its holdings in shares of Gilead Sciences by 2.6% in the 4th quarter. Capital Investment Advisors LLC now owns 387,492 shares of the biopharmaceutical company’s stock worth $35,793,000 after buying an additional 9,791 shares during the last quarter. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.